Why do we age when we get older? Epigenetics may hold the answer – but could it one day help us turn back the clock? Professor Wolf Reik from the Department of Physiology, Development and Neuroscience at the University of Cambridge and Dr Oliver Stegle from the European Bioinformatics Institute look at the ‘epigenetic clock’ in The Conversation.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
A team of scientists who a few years ago identified a major pathway that leads to brain cell death in mice, have now found two drugs that block the pathway and prevent neurodegeneration. The drugs caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials.
Algorithm matches genetic variation to disease symptoms and could improve diagnosis of rare diseases19 Apr 2017
A faster and more accurate method of identifying which of an individual’s genes are associated with particular symptoms has been developed by a team of researchers from the UK and Saudi Arabia. This new approach could enable scientists to take advantage of recent developments in genome sequencing to improve diagnosis and potential treatment options.
Scientists at the University of Cambridge and the Wellcome Trust Sanger Institute have created a new technique that simplifies the production of human brain and muscle cells - allowing millions of functional cells to be generated in just a few days. The results published today in Stem Cell Reports open the door to producing a diversity of new cell types that could not be made before in order to study disease.
Cambridge Academy of Therapeutic Sciences aims to create world-leading industry-academia collaborations09 Mar 2017
The Cambridge Academy of Therapeutic Sciences (CATS), a new initiative that aims to establish a world-leading platform for collaboration between academia and industry in the development of therapeutics, will be launched today by the Vice-Chancellor of the University of Cambridge.
Cambridge scientists have received two of the biggest funding grants ever awarded by Cancer Research UK, with the charity set to invest £40 million over the next five years in two ground-breaking research projects in the city.
Iron deficiency can be fatal. But in countries where patients are also likely to have other serious diseases, so too can the iron supplements used to treat it. Nearly 12 years ago, Dora Pereira – sometimes referred to as ‘The Iron Lady’ – was part of the team who had an idea for a new supplement. She now leads its clinical trial in The Gambia.
DNA sequencing has defined a new genetic disorder that affects movement, enabling patients with dystonia — a disabling condition that affects voluntary movement — to be targeted for treatment that brings remarkable improvements, including restoring independent walking.
Researchers from the Wellcome Trust Sanger Institute and the University of Cambridge have created sOPTiKO, a more efficient and enhanced inducible CRISPR genome editing platform. Today, in the journal Development, they describe how the freely available single-step system works in every cell in the body and at every stage of development. This new approach will aid researchers in developmental biology, tissue regeneration and cancer.